Stockwatch: Is it time to give no quarter?
This article was originally published in Scrip
Does quarterly reporting actually matter at all? In the weeks of the quarterly reporting season, fund managers wake up to more than 50 new emails each morning. Then they glue themselves to their computer screens and dial into conference calls. What starts as a gentle, reasonably benign trickle of information (scripintelligence.com, 18 April 2013) becomes an acute hemorrhage of mixed results announcements, research notes and news reports.
You may also be interested in...
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.
It is one thing to aspire to build a rival to another company’s banner therapeutic franchise, but quite another to start from the ground up, especially when your form in that area is mixed.